Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies
Cancers · 27.09.2024 · 16 (19) · 3288
DOI: 10.3390/cancers16193288 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.09.2024. Verfasst von Kevin Guanwen Shim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Mayo Clinic Hematological Malignancies Program, Paula and Roger Riney Foundation.
Abstract (Originalsprache)
Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting therapies (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical trial and real-world data, these therapies have demonstrated high rates of deep clinical response, and some are now approved for second-line treatment for relapsed MM. The deep and sustained clinical responses these therapies are capable of inducing will require sophisticated response monitoring to provide meaningful information for patient care. Obtaining measurable residual disease (MRD) negativity has been validated as an independent positive prognostic marker for progression-free survival (PFS) and overall survival (OS) in both newly diagnosed and relapsed refractory patients with multiple myeloma. Assessment for MRD negativity was performed in all of the trials for FDA-approved TRT. Here, we summarize pertinent data for MRD assessment following TRT in MM and provide a rationale and structured framework for conducting MRD testing post TRT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.
ORCID-Profile: Kevin Guanwen Shim, Rafael Fonseca
Förderung
- NCI NIH HHS
- Mayo Clinic Hematological Malignancies Program
- Paula and Roger Riney Foundation
- Mayo Clinic and NCI
Zitieren
APA
Shim, K. G., & Fonseca, R. (2024). Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies. Cancers, 16(19), 3288. https://doi.org/10.3390/cancers16193288
Vancouver
Shim KG, Fonseca R. Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies. Cancers. 2024;16(19):3288. doi:10.3390/cancers16193288
BibTeX
@article{Shim2024,
author = {Shim, Kevin Guanwen and Fonseca, Rafael},
title = {Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies},
journal = {Cancers},
year = {2024},
volume = {16},
number = {19},
pages = {3288},
doi = {10.3390/cancers16193288}
}
EUVIMED